Enhancing effect of lonidamine on the inhibition of mitochondrial respiration by adriamycin. 1987

A Bagnato, and C Bianchi, and A Caputo, and B Silvestrini, and A Floridi
Regina Elena Institute for Cancer Research, Rome, Italy.

Pretreatment of rat liver mitochondria with lonidamine (LND), 1-(2,4 dichlorobenzyl)-1 H-indazol-3-carboxylic acid, increases their susceptibility to respiratory inhibition by adriamycin (ADM). Because LND does not inhibit the rate of oxygen consumption at the concentrations used, its potentiating effect may be exerted by favoring the interaction of ADM molecules with their sites in the inner mitochondrial membrane. LND does not modify the permeability on the inner membrane for large molecules. However, its enhancing effect can be ascribed to a modified permeability of the outer mitochondrial membrane which may represent a barrier for ADM entry.

UI MeSH Term Description Entries
D007191 Indazoles A group of heterocyclic aromatic organic compounds consisting of the fusion of BENZENE and PYRAZOLES. Indazole
D008930 Mitochondria, Liver Mitochondria in hepatocytes. As in all mitochondria, there are an outer membrane and an inner membrane, together creating two separate mitochondrial compartments: the internal matrix space and a much narrower intermembrane space. In the liver mitochondrion, an estimated 67% of the total mitochondrial proteins is located in the matrix. (From Alberts et al., Molecular Biology of the Cell, 2d ed, p343-4) Liver Mitochondria,Liver Mitochondrion,Mitochondrion, Liver
D010101 Oxygen Consumption The rate at which oxygen is used by a tissue; microliters of oxygen STPD used per milligram of tissue per hour; the rate at which oxygen enters the blood from alveolar gas, equal in the steady state to the consumption of oxygen by tissue metabolism throughout the body. (Stedman, 25th ed, p346) Consumption, Oxygen,Consumptions, Oxygen,Oxygen Consumptions
D010539 Permeability Property of membranes and other structures to permit passage of light, heat, gases, liquids, metabolites, and mineral ions. Permeabilities
D011720 Pyrazoles Azoles of two nitrogens at the 1,2 positions, next to each other, in contrast with IMIDAZOLES in which they are at the 1,3 positions.
D002259 Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone A proton ionophore that is commonly used as an uncoupling agent in biochemical studies. Carbonyl Cyanide para-Trifluoromethoxyphenylhydrazone,FCCP,(4-(Trifluoromethoxy)phenyl)hydrazonopropanedinitrile,Carbonyl Cyanide p Trifluoromethoxyphenylhydrazone,Carbonyl Cyanide para Trifluoromethoxyphenylhydrazone,Cyanide p-Trifluoromethoxyphenylhydrazone, Carbonyl,Cyanide para-Trifluoromethoxyphenylhydrazone, Carbonyl,p-Trifluoromethoxyphenylhydrazone, Carbonyl Cyanide,para-Trifluoromethoxyphenylhydrazone, Carbonyl Cyanide
D003573 Cytochrome b Group Cytochromes (electron-transporting proteins) with protoheme (HEME B) as the prosthetic group. Cytochromes Type b,Cytochromes, Heme b,Group, Cytochrome b,Heme b Cytochromes,Type b, Cytochromes,b Cytochromes, Heme,b Group, Cytochrome
D004317 Doxorubicin Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN. Adriamycin,Adriablastin,Adriablastine,Adriblastin,Adriblastina,Adriblastine,Adrimedac,DOXO-cell,Doxolem,Doxorubicin Hexal,Doxorubicin Hydrochloride,Doxorubicin NC,Doxorubicina Ferrer Farm,Doxorubicina Funk,Doxorubicina Tedec,Doxorubicine Baxter,Doxotec,Farmiblastina,Myocet,Onkodox,Ribodoxo,Rubex,Urokit Doxo-cell,DOXO cell,Hydrochloride, Doxorubicin,Urokit Doxo cell
D004357 Drug Synergism The action of a drug in promoting or enhancing the effectiveness of another drug. Drug Potentiation,Drug Augmentation,Augmentation, Drug,Augmentations, Drug,Drug Augmentations,Drug Potentiations,Drug Synergisms,Potentiation, Drug,Potentiations, Drug,Synergism, Drug,Synergisms, Drug
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

A Bagnato, and C Bianchi, and A Caputo, and B Silvestrini, and A Floridi
May 1994, Biochemical pharmacology,
A Bagnato, and C Bianchi, and A Caputo, and B Silvestrini, and A Floridi
January 2016, The Journal of biological chemistry,
A Bagnato, and C Bianchi, and A Caputo, and B Silvestrini, and A Floridi
January 1987, Comparative biochemistry and physiology. C, Comparative pharmacology and toxicology,
A Bagnato, and C Bianchi, and A Caputo, and B Silvestrini, and A Floridi
October 1990, Biochemical pharmacology,
A Bagnato, and C Bianchi, and A Caputo, and B Silvestrini, and A Floridi
January 1983, Biochimica et biophysica acta,
A Bagnato, and C Bianchi, and A Caputo, and B Silvestrini, and A Floridi
October 2011, Archives of biochemistry and biophysics,
A Bagnato, and C Bianchi, and A Caputo, and B Silvestrini, and A Floridi
January 1988, Comptes rendus des seances de la Societe de biologie et de ses filiales,
A Bagnato, and C Bianchi, and A Caputo, and B Silvestrini, and A Floridi
January 1986, Anticancer research,
A Bagnato, and C Bianchi, and A Caputo, and B Silvestrini, and A Floridi
September 1981, Journal of molecular and cellular cardiology,
A Bagnato, and C Bianchi, and A Caputo, and B Silvestrini, and A Floridi
September 1986, Molecular and biochemical parasitology,
Copied contents to your clipboard!